Compare STTK & EROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | STTK | EROK |
|---|---|---|
| Founded | 2016 | 2023 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Oil & Gas Production |
| Sector | Health Care | Energy |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 652.4M | 623.3M |
| IPO Year | 2020 | 2026 |
| Metric | STTK | EROK |
|---|---|---|
| Price | $5.65 | $21.76 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 11 | 6 |
| Target Price | $15.22 | ★ $28.83 |
| AVG Volume (30 Days) | ★ 1.1M | 152.7K |
| Earning Date | 11-05-2026 | 11-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 53.02 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,000,000.00 | N/A |
| Revenue This Year | N/A | $154.84 |
| Revenue Next Year | N/A | $17.21 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.70 | $20.06 |
| 52 Week High | $8.33 | $27.42 |
| Indicator | STTK | EROK |
|---|---|---|
| Relative Strength Index (RSI) | 35.85 | 40.27 |
| Support Level | $3.55 | $20.13 |
| Resistance Level | $7.83 | $22.53 |
| Average True Range (ATR) | 0.46 | 0.99 |
| MACD | -0.01 | -0.10 |
| Stochastic Oscillator | 5.65 | 38.19 |
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.
EagleRock Land LLC is a surface-focused land management company, focused on providing access to land, resources, and infrastructure assets in the Permian Basin, including areas in Texas and New Mexico. Its assets support oil and natural gas development, as well as activities related to power generation, water infrastructure, and other industries. Through its land position and integrated infrastructure assets, the company generates revenue and royalties from completion and production-based activities, including surface damages, ROWs, easements, commercial water supply and produced water recycling, handling and disposal and other surface and subsurface related activities.